PL2828259T3 - Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3 - Google Patents

Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3

Info

Publication number
PL2828259T3
PL2828259T3 PL13763998T PL13763998T PL2828259T3 PL 2828259 T3 PL2828259 T3 PL 2828259T3 PL 13763998 T PL13763998 T PL 13763998T PL 13763998 T PL13763998 T PL 13763998T PL 2828259 T3 PL2828259 T3 PL 2828259T3
Authority
PL
Poland
Prior art keywords
flt3 inhibitors
substituted pyridopyrimidine
pyridopyrimidine compounds
compounds
substituted
Prior art date
Application number
PL13763998T
Other languages
English (en)
Inventor
Hong Woo Kim
Hee Kyu Lee
Ho-Juhn Song
Jaekyoo Lee
Jong Sung Koh
Jung-Ho Kim
Se Won Kim
In Yong Lee
Original Assignee
Oscotec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscotec, Inc. filed Critical Oscotec, Inc.
Publication of PL2828259T3 publication Critical patent/PL2828259T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/305Mercury compounds
    • A61K31/31Mercury compounds containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13763998T 2012-03-22 2013-03-15 Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3 PL2828259T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614274P 2012-03-22 2012-03-22
PCT/US2013/032575 WO2013142382A1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
EP13763998.5A EP2828259B1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Publications (1)

Publication Number Publication Date
PL2828259T3 true PL2828259T3 (pl) 2019-02-28

Family

ID=49223277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13763998T PL2828259T3 (pl) 2012-03-22 2013-03-15 Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3

Country Status (22)

Country Link
US (1) US8877763B2 (pl)
EP (1) EP2828259B1 (pl)
JP (1) JP6101341B2 (pl)
KR (1) KR102011770B1 (pl)
CN (1) CN104428298B (pl)
AU (1) AU2013235344B2 (pl)
BR (1) BR112014023460B1 (pl)
CA (1) CA2868156C (pl)
CL (1) CL2014002505A1 (pl)
EA (1) EA031267B1 (pl)
ES (1) ES2694223T3 (pl)
HK (1) HK1208453A1 (pl)
IL (1) IL234802B (pl)
IN (1) IN2014MN02082A (pl)
MX (1) MX360912B (pl)
MY (1) MY184858A (pl)
NZ (1) NZ700283A (pl)
PL (1) PL2828259T3 (pl)
SG (1) SG11201405942RA (pl)
TR (1) TR201816480T4 (pl)
WO (1) WO2013142382A1 (pl)
ZA (1) ZA201407588B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3060562T (pt) * 2013-10-21 2021-09-02 Genosco Compostos de pirimidina substituídos e sua utilização como inibidores da syk
CA2952083C (en) * 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
EP3804725A3 (en) 2014-11-17 2021-07-07 Rhode Island Hospital Nanomaterial compositions, synthesis, and assembly
SG11202013029UA (en) * 2018-06-27 2021-01-28 Oscotec Inc Pyridopyrimidinone derivatives for use as axl inhibitors
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
KR102230721B1 (ko) 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110327347B (zh) * 2019-08-16 2021-06-01 陕西科技大学 G-749在制备抗真菌药物中的应用
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
KR102440707B1 (ko) 2022-07-10 2022-09-05 이우미 공장 추천 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020070520A (ko) * 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
KR100571339B1 (ko) * 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
ES2243568T3 (es) * 2000-08-31 2005-12-01 F. Hoffmann-La Roche Ag 7-oxo-piridopirimidinas.
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
EP2330909B1 (en) * 2008-08-12 2013-09-18 GlaxoSmithKline LLC Chemical compounds
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
WO2011022473A1 (en) * 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
EP2493313B1 (en) * 2009-10-29 2017-12-13 Genosco Kinase inhibitors

Also Published As

Publication number Publication date
MX2014011354A (es) 2014-12-05
BR112014023460B1 (pt) 2020-09-01
EA201491747A1 (ru) 2015-10-30
KR20140144709A (ko) 2014-12-19
JP6101341B2 (ja) 2017-03-22
EP2828259B1 (en) 2018-08-08
CA2868156C (en) 2020-07-28
ZA201407588B (en) 2015-11-25
CN104428298B (zh) 2017-03-01
EP2828259A4 (en) 2015-08-19
AU2013235344A1 (en) 2014-10-09
MY184858A (en) 2021-04-27
SG11201405942RA (en) 2014-10-30
EP2828259A1 (en) 2015-01-28
IN2014MN02082A (pl) 2015-08-21
EA031267B1 (ru) 2018-12-28
MX360912B (es) 2018-11-22
ES2694223T3 (es) 2018-12-19
US8877763B2 (en) 2014-11-04
HK1208453A1 (en) 2016-03-04
CA2868156A1 (en) 2013-09-26
IL234802B (en) 2018-10-31
CL2014002505A1 (es) 2015-10-02
US20130274274A1 (en) 2013-10-17
AU2013235344B2 (en) 2017-03-16
TR201816480T4 (tr) 2018-11-21
CN104428298A (zh) 2015-03-18
WO2013142382A1 (en) 2013-09-26
JP2015510942A (ja) 2015-04-13
NZ700283A (en) 2016-08-26
KR102011770B1 (ko) 2019-08-19

Similar Documents

Publication Publication Date Title
HK1208453A1 (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors flt3
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
EP2920149A4 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T-HEMMER AND USES THEREOF
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
HK1210771A1 (en) Azaindole derivatives which act as pi3k inhibitors
ZA201406082B (en) Use of ccr3-inhibitors
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors 2h--4- bace
HK1212331A1 (en) 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4--
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
IL239245A0 (en) A new use of Eclidenium
HK1214244A1 (zh) 咪唑並吡啶衍生物
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors
GB201213726D0 (en) Novel compounds and their use